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Fazal Danish1, Andrew Johnson7, Berta A Castillo3, Yun R Li3, Hakon Hakonarson3, Sarah G Buxbaum8,
Tom Palmer9, Michael Y Tsai10, Leslie A Lange11, Shah Ebrahim12, George Davey Smith2, Debbie A Lawlor2,
Aaron R Folsom6, Ron Hoogeveen13, Alex Reiner14, Brendan Keating3,15,16 and Ian NM Day*,1,16
Gallbladder disease (GBD) has an overall prevalence of 10–40% depending on factors such as age, gender, population, obesity
and diabetes, and represents a major economic burden. Although gallstones are composed of cholesterol by-products and are
associated with obesity, presumed causal pathways remain unproven, although BMI reduction is typically recommended. We
performed genetic studies to discover candidate genes and define pathways involved in GBD. We genotyped 15 241 women of
European ancestry from three cohorts, including 3216 with GBD, using the Human cardiovascular disease (HumanCVD)
BeadChip containing up to ~53 000 single-nucleotide polymorphisms (SNPs). Effect sizes with P-values for development of GBD
were generated. We identify two new loci associated with GBD, GCKR rs1260326:T4C (P=5.88×10−7, ß=−0.146) and
TTC39B rs686030:C4A (P=6.95x10−7, ß=0.271) and detect four independent SNP effects in ABCG8 rs4953023:G4A
(P=7.41×10−47, ß=0.734), ABCG8 rs4299376:G4T (P=2.40×10−18, ß=0.278), ABCG5 rs6544718:T4C
(P=2.08×10−14, ß=0.044) and ABCG5 rs6720173:G4C (P=3.81×10−12, ß=0.262) in conditional analyses taking
genotypes of rs4953023:G4A as a covariate. We also delineate the risk effects among many genotypes known to influence
lipids. These data, from the largest GBD genetic study to date, show that specific, mainly hepatocyte-centred, components of
lipid metabolism are important to GBD risk in women. We discuss the potential pharmaceutical implications of our findings.
European Journal of Human Genetics (2016) 24, 106–112; doi:10.1038/ejhg.2015.63; published online 29 April 2015
INTRODUCTION
Gallbladder disease (GBD) is a major cause of morbidity, hospital
admission, surgical intervention and economic burden and is caused
by gallstones.1 Gallstones occur in 10–40% of adults in developed
countries,2 predominantly in women.3 The incidence increases with
age and other factors such as obesity and diabetes, although there are
differences between men and women in the determinants of GBD.4
These differences make advisable the analysis of the genetic basis of
GBD separate by sex. Causes of morbidity include biliary colic,
cholecystitis, choledocholithiasis and pancreatitis.5 In the USA,
4700 000 cholecystectomies are undertaken per year.6 Large genetic
studies have shown that the additive genetic heritability of sympto-
matic gallstones ranges from 25 to 29%.7,8
In developed countries, most gallstones are formed of cholesterol,
but pigment stones consisting substantially of calcium bilirubinate
predominate in regions where bacterial and parasitic infections of the
biliary tree, and hemolysis, are common.9 Exogenous estrogens are a
risk factor, as are fibrates.10
Some symptomatic patients require surgical intervention, whereas
prevention through measures targeting important causal pathways
should avoid all morbidity and sequelae. Long-term statin use was
associated with reduced GBD in a recent observational case–control
design, but bias and confounding cannot be ruled out,11 and results of
long-term randomized controlled trials are not yet available.
Although family-based genetic linkage studies of GBD have met
with limited success, inbred mouse studies12 and human genome-wide
association studies (GWASs)13 converged on one notable locus, the
head-to-head gene pair ABCG5/ABCG8, which together encode a
heterodimeric transporter responsible for apical cholesterol secretion
from both hepatocytes and enterocytes. However, a systems biology
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view must be taken since liver cell homeostasis compensates lesser
absorption (more secretion) with more endogenous cholesterol
synthesis.
We therefore conducted a large-scale genetic association study of
GBD. This was conducted in women sampled from the general
population. This design avoided potential selection bias of genotypes;
with high single-nucleotide polymorphism (SNP) density coverage
including many loci already well established to be involved in lipid
metabolism or obesity. We analyzed our data in relation to this




Genetic association analyses were conducted in order to identify candidate
SNPs associated with GBD. Fine mapping of causal loci and effects of lipids
were also considered. Only women were tested as two of the cohorts analyzed
included only women. Findings derived from this work will therefore be
applicable only to women.
Study descriptions and phenotype definitions are shown in Supplementary
Information.
Data Access for the NHLBI Candidate gene Association Resource (CARe).
The NHLBI initiated the CARe to create a shared genotype/phenotype resource
for analyses of the association of genotypes with phenotypes relevant to the
mission of the NHLBI. The resource comprises nine cohort studies funded by
the NHLBI including: Atherosclerosis Risk in Communities (ARIC), Cardio-
vascular Health Study (CHS), Cleveland Family Study (CFS), Coronary Artery
Risk Development in Young Adults (CARDIA), Framingham Heart Study
(FHS), Jackson Heart Study (JHS), Multi-Ethnic Study of Atherosclerosis
(MESA) and the Sleep Heart Health Study (SHHS). A database of genotype and
phenotype data was created that includes records for ~ 41 000 study participants
with ~ 50 000 SNPs from 42000 selected candidate genes. Data from
individual cohorts such as ARIC are available to the approved investigators
upon submission of data requests through the dbGaP portal.
Genotyping and quality control
Genotype quality control characteristics from the three data sets are described
in Supplementary Table 2. Genomic control inflation factors (λ) were 1.00 for
all three cohorts. Genotyping was performed using the Human cardiovascular
disease (HumanCVD) BeadChip (Illumina, San Diego, CA, USA), also known
as the ITMAT-Broad-CARe (IBC) array as previously described.14 The ARIC
and BWHHS used the IBCv2 array, which contained up to 49 240 SNPs,
whereas the WHI used the IBCv3 array, which contained up to 53 400 SNPs
(containing the entire v2 content plus an additional ~ 4200 SNPs from updated
metabolic GWAS findings in the literature from 2007 to 2008). All SNPs were
clustered into genotypes using the Illumina Beadstudio software and subjected
to quality control filters at the sample and SNP level, separately within each
cohort. Samples were excluded for individual call rates o90%, gender
mismatch and duplicate discordance. SNPs were removed for call rates
o95% or Hardy–Weinberg disequilibrium Po10–7. Because of the low
frequency SNPs included in the design, and the aim to capture low frequency
variants of large effect across the large dataset, we filtered only on minor allele
frequency (MAF)o0.01. Following identification of the TTC39B SNP rs581080
in WHI that was absent in IBCv2, all BWHHS samples were genotyped for
rs581080 using the KASPar system (KBiosciences, Essex, UK).15
Statistical analyses
Only women of European ancestry were included. For each of the three studies,
we verified self-reported ethnicity by multidimensional scaling analysis of
identity-by-state distances as implemented in PLINK,16 including HapMap
panels as reference standards. After pruning of SNPs in linkage disequilibrium
(LD; r240.3), Eigenstrat was used to compute principal components (PCs) on
the subset of non-excluded individuals for use as covariates in the regression
analyses to control for the influence of population admixture.17,18
GBD association analysis was performed in each study using an additive
genetic model. We performed association analyses using GBD case/control
adjusted for age and additionally adjusted for PCs if population structure was
evident. Analyses adjusting for BMI were also performed. The λ was calculated
in each case–control study and used for within-study correction before meta-
analysis. Meta-analysis was performed using a fixed-effect standard error-based
approach using METAL (1). The Candidate gene Association Resource (CARe)
IBC array studies,19 determined that after accounting for LD, the effective
number of independent tests was ~ 20 500 for Europeans producing an
experimental or ‘array-wide’ statistical threshold of P= 2.4× 10− 6, respectively,
to maintain a false-positive rate of 5%,20 which has been employed in
numerous studies to date.21–24 We also highlight loci significantly associated
at a more conventional genome-wide significant threshold of Po5.0× 10− 8.
Loci harboring marginally significant evidence for association at Po10− 5
were examined for independent signals via regression analyses in PLINK.16 A
term was added to the regression model including the lead SNP as a covariate,
and SNPs within the same candidate gene, or ± 200 kb if the candidate gene
region was o200 kb, were evaluated for maintaining array-wide significance.
HDL-adjusted meta-analysis and conditional analysis were performed in the
WHI and ARIC cohorts in which individual-level genotype data were available.
A locus-specific Bonferroni correction was applied to determine the significance
of independent signals.
Regional association plots for the genomic regions associated with GBD were
constructed using the online tool LocusZoom (http://csg.sph.umich.edu/
locuszoom/). When drawing the plots, the genome build HG18 was selected
to provide the genome coordinates of SNPs. 1000 Genome CEU was used as
the LD population.
The variance explained (adjusted R2) by associated SNPs (defined to be with
P-valueo1× 10− 4 in the primary genetic association tests) was calculated
within cohorts with individual-level genotype and phenotype data available
(ARIC and WHI) using a linear regression model incorporating the adjustment
by covariates of age and three PC's. The average variance explained, weighted
by the sample size of each contributing study, is reported.
Fine mapping of candidate loci
Fine mapping of candidate loci has been performed using an approach we
previously developed (Sequential Sentinel SNP Regional Association Plot, SSS-
RAP)25 (software available at http://apps.biocompute.org.uk/sssrap/sssrap.cgi).
SSS-RAP, together with conditional analysis, was used to identify independent
signals. In short, this method is biologically driven and considers the relation-
ship between LD and linear/logistic regression for pairwise SNPs. We adopted
the additive model, typical for genes with small effect, and transformed the
effect of a sentinel SNP to the predicted effect for a possibly dependent SNP.
There are 77 SNPs in the ABCG5/8 locus designed on the IBC array, thus we
used locus-wide significance level of 0.05/77= 6.49× 10− 4 as the cutoff for
conditional analysis. In the first round conditional analysis, we took genotypes
of the lead SNP (rs4953023:G4A) in the un-conditional meta-analysis, redid
association tests by adjusting its genotypes as a covariate in each individual-level
cohort, and meta-analyzed the results. Then in the second round, we extracted
the lead SNP of the first round conditional analysis (rs4299376:G4T), took the
combination of genotypes for SNPs rs4953023:G4A and rs4299376:G4T as a
covariate, and repeated the above procedure. We performed third and fourth
rounds similarly. Within the ABCG5-8 region, 360 SNPs were analysed from
the 1000 genomes database based on 26 different populations from many
different worldwide locations (http://www.1000genomes.org/). A total of 118
SNPs remained after excluding SNPs in perfect LD (r2= 1). A random subset of
SNPs not in the meta-analysis was excluded, with the remaining SNPs analysed
using SSS-RAP. The rationale of random exclusion was to keep a representative
sample of the study. Using this approach, 10/118 SNPs remained significant as
signals in the meta-analysis.
Associations of lipid SNPs with GBD
Median − log10 P-values were analyzed for 65 loci previously reported to
associate with plasma lipid levels26 in comparison with the distribution of
median − log10 P-values generated by 10 000 simulations using random
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sampling of 65 loci for each set of simulations. These Monte Carlo simulations
were performed in R.
Representations of the histogram of median estimates were performed using
the ‘hist’ function in the basic package of R (http://svn.r-project.org/R/trunk/
src/library/graphics/R/hist.R), and the quantile–quantile (QQ) plots were also




Seventeen SNPs with call rates 495% and Hardy–Weinberg disequi-
librium (P410–7) with MAF 40.01 showed significant association
with GBD at a level of P≤ 2.4x10− 6 in our meta-analysis (Table 1).
Fourteen of these variants localized to the ABCG5/ABCG8 locus
(Table 1), including the strongest signal found in our study (with
rs4953023:G4A having the strongest value, P= 7.41x10− 47). The
three remaining SNPs corresponded to the genes GCKR and TTC39B
(Table 1). A less stringent threshold of P≤ 10− 5 revealed 18 more
SNPs that showed marginally significant association with GBD at a
level of P≤ 10− 5 in our meta-analysis (Supplementary Table 3). One
of these variants localized to the ABCG5/ABCG8 locus. The 17
remaining SNPs corresponded to the genes TTC39B, GCKR,
C2orf16, CCL20, RUNX1, EIF2B4, MMP24, CYP4F2, RIPK1, ZNF512
and GAA (Supplementary Table 3). The effect sizes and standard
errors are also shown in Table 1 and Supplementary Table 3.
As there are two versions of the IBC array used in this study, this
resulted in missingness for some SNPs across the cohorts. Table 1
shows the concordance of the direction of the effect found in all three
cohorts (ARIC, BWHHS and WHI). There is concordance of direction
for nine ABCG5/ABCG8 SNPs, discordance for none, and incomplete
information for six (five of the six SNPS were present on the version 3
array only). With regard to the other genes, we found the same
direction of effect in all three cohorts for SNPs in GCKR, C2orf16,
CCL20, RUNX1, MMP24, CYP4F2, RIPK1 and ZNF512. TTC39B
showed incomplete information (Supplementary Table 3).
Results for HDL-adjusted meta-analysis are shown in
Supplementary Table 4. In summary, after adjusting for HDL, all of
the ABCG5/8 SNPs with the exception of rs4148189:C4T and
rs6544713:T4C are significant considering the array-wide significance
level, whereas TTC39B SNPs are not significant considering the array-
wide significance level. Most strong hit for this gene is rs686030:C4A,
with P= 0.0038. GCKR SNP rs1260326 it is still marginally significant
(P= 1.01× 10− 5 after the HDL adjustment).
SNPs with P-value o1× 10− 4 (37 SNPs in total) explain 0.0808 of
the variance in ARIC (note 11 SNPs are not genotyped in ARIC),
while they explain 0.0917 of the variance in WHI (one ABCG5 SNP
rs4148191:G4T was not genotyped in WHI).
Conditional analyses and regional association plots
Our conventional conditional analysis detected four independent SNP
effects in ABCG8/5 rs4953023:G4A, rs4299376:G4T, rs6544718:
T4C and rs6720173:G4C (Supplementary Table 6) A different
method to perform conditional analyses (SSS-RAP), after setting
rs4953023:G4A as a top hit (lowest P-value), identified three SNPs
(rs10208987:T4G, rs4299376:G4T and rs3806470: G4A) as possi-
ble independent signals associated with GBD. The possible indepen-
dence among these SNPs was supported by the low pairwise r2 values
observed (r2o0.22).
High degrees of heterogeneity when combining the three cohorts
and unavailability of individual-level data in BWHHS are possible
causes to explain differences between conditional analysis and SSS-
RAP results.
Regional association plots are shown in Supplementary
Figures 4–15.
Table 1 Association of SNPs with GBD in the ARIC, BWHHS and WHI IBC array studies
Marker namea A1 A2 Freq1 Effect SE P-value Direction HetChiSq HetPVal CHR Hg18_bp Gene GeneAnno
rs4953023 a g 0.0657 0.7335 0.051 7.41×10−47 +++ 7.219 0.02706 2 43927504 ABCG8 Intron
rs6756629 a g 0.0651 0.6297 0.0682 2.54×10−20 +nn 0 1 2 43918594 ABCG8 Near-gene-5
rs4299376 t g 0.6846 0.278 0.0318 2.40×10−18 +++ 5.848 0.05371 2 43926080 ABCG8 Intron
rs10208987 t g 0.9208 −0.3678 0.049 6.37×10−14 −−− 2.587 0.2743 2 43896639 ABCG5 Intron
rs10439467 t c 0.0616 0.3825 0.0546 2.55×10−12 +++ 8.025 0.01809 2 43901850 ABCG5 Intron
rs6720173 c g 0.1585 0.2618 0.0377 3.81×10−12 +++ 1.63 0.4426 2 43893905 ABCG5 Coding-nonsynon, cds-reference
rs6709904 a g 0.8846 −0.3729 0.0546 8.10×10−12 −nn 0 1 2 43933828 ABCG8 Intron
rs4953019 a g 0.0749 0.3266 0.0506 1.11×10−10 +++ 2.523 0.2832 2 43896897 ABCG5 Intron
rs2278357 t c 0.1607 0.2379 0.0374 2.10×10−10 +++ 2.093 0.3512 2 43893343 ABCG5 Untranslated
rs10201851 t c 0.8821 −0.2565 0.0427 1.82×10−9 −−− 3.601 0.1652 2 43900089 ABCG5 Intron
rs6544713 a g 0.3125 −0.2385 0.0401 2.69×10−9 −nn 0 1 2 43927385 ABCG8 Intron
rs4148189 t c 0.113 0.2446 0.0432 1.54×10−8 +++ 3.423 0.1806 2 43901034 ABCG5 Intron
rs4148191 a c 0.0721 0.5056 0.0948 9.52×10−8 n+n 0 1 2 43896408 ABCG5 Intron
rs4148196 c g 0.8364 −0.2484 0.0475 1.73×10−7 −nn 0 1 2 43891418 ABCG5 3 downstream
rs1260326 t c 0.4144 −0.1463 0.0293 5.88×10−7 −−n 3.152 0.2068 2 27584444 GCKR Coding-nonsynon, cds-reference
rs686030 a c 0.8581 0.271 0.0546 6.95×10−7 +nn 0 1 9 15294782 TTC39B Intron
rs661048 a g 0.8663 0.2664 0.0561 2.04×10−6 +nn 0 1 9 15287629 TTC39B Intron
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CHR, chromosome; GBD, gallbladder disease; IBC, ITMAT-Broad-CARe; SNP, single-nucleotide polymorphism.
Marker name is SNP name; A1 is allele 1 (ref allele); A2 is allele 2; effect is the beta coefficient; P-value. Direction: + indicates the same direction of effect; − indicates different direction; n
indicates no data available for that particular SNP. Cohorts are in order, WHI/ARIC/BWHHS. HetChiSq=heterogeneity test statistic, HetPVal=heterogeneity P-value. Gene, gene name, GeneAnno,
location of the SNP within the gene.
aFull names of these SNPs are rs4953023 (NT_022184.16:g.27700742G4A), rs6756629 (NT_022184.16:g.27691832G4A), rs4299376 (NT_022184.16:g.27699318G4T), rs10208987
(NT_022184.16:g.27669877T4G), rs10439467 (NT_022184.16:g.27675088C4T), rs6720173 (NT_022184.16:g.27667143G4C), rs6709904 (NT_022184.16:g.27707066A4G),
rs4953019 (NT_022184.16:g.27670135G4A), rs2278357 (NT_022184.16:g.27666581C4T), rs10201851 (NT_022184.16:g.27673327T4C), rs6544713 (NT_022184.16:
g.27700623T4C), rs4148189 (NT_022184.16:g.27674272C4T), rs4148191 (NT_022184.16:g.27669646C4A), rs4148196 (NT_022184.16:g.27664656C4G), rs1260326
(NT_022184.16:g.11361954T4C), rs686030 (NT_008413.19:g.15294784C4A), rs661048 (NT_008413.19:g.15287631G4A.
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LD involving loci significantly associated with GBD
LD results for loci significantly associated with GBD are shown in
Supplementary Information.
Analyses of loci in lipid pathway
From the 95 independent loci previously reported to be associated
with blood lipid levels,26 it was possible to subject 65 to a test using
IBC array data (Supplementary Table 5). Figure 1a shows the QQ plots
relating the distribution of significant associations for GBD observed
for SNPs representing 65 independent loci previously reported to
associate with plasma lipid levels, compared with a random set. Out of
65 SNPs, 59 showed an observed P-value above the expected P-value
in a QQ plot. The observed distribution (for lipid-associated loci) was
significantly different than the expected distribution (for a random
set). This is in accordance with a combined effect of these SNPs both
on GBD and on plasma lipid levels variation.
Figure 1b shows results for Monte Carlo simulations analyzing the
median − log10 P-value of 10 000 samples of groups of 65 random
SNPs in IBC. The observed median value for the 65 lipid-associated
loci was 1.06 (mean= 1.07, SD= 0.19). A median − log10 P-value
greater than that observed for the lipid loci set was only observed in
1.7% of random samplings.
In our analysis, a handful of loci influencing either LDLc or
triglycerides showed the most prominent associations with GBD.
Specifically, these were rs4299376:G4T in ABCG5/ABCG8 (see
above); rs2081687:T4C in CYP7A1 (our proxy rs8192870:T4G has
an r2= 0.806 with rs2081687:T4C, P= 0.021 for GBD); rs5756931:
A4G in PLA2G6 (our proxy rs4820314:C4T r2= 0.661, P= 0.0022
for GBD); rs28385705:T4C in PCSK9 (P= 0.011) and rs483140:
G4C in LIPC (P= 0.0037). Details about all the associations are
presented in Supplementary Table 3.
Pathway analysis
Tissue expression and pathway rationale were evaluated to support the
associated gene loci reported in Table 1. We consulted a recent survey
of tissue expression by RNA sequencing27 for transcripts showing
particularly relevant expression to GBD. We noted that CCL20
(highest expression in gallbladder), ABCG5, ABCG8, CYP4F2, GCKR,
RUNX1 and TTC39B all showed predominant expression in hepato-
biliary and gastrointestinal tissues, providing biological support for a
role in GBD. Extending our analysis further, we used GeneGO
Metacore (Thomson Reuters, New York, NY, USA) to evaluate the
13 genes for direct interaction with 142 genes previously linked to
GBD in the literature by Medical Subject Headings terms. Five genes
(ABCG5, ABCG8, CCL20, RUNX1 and CYP4F2) showed direct
interaction with genes linked to GBD by MESH in a network of
directly interacting genes. Notably, the RUNX1 gene interacts directly
with 13 other GBD-linked genes, whereas CCL20 interacts with three
GBD-linked genes, suggesting multiple levels of biological support for
both genes. Supplementary Figures 2 and 3 show a sub-network from
this analysis based only on direct interactors of the genes reported in
this study.
Analysis of potential pharmacologic targets
Five of the novel genes reported here have available small molecule
modulators (mainly inhibitory or binding) based on a query of the
ChEMBL database (www.ebi.ac.uk/chembldb/). The genes are listed
with the number of tool compounds in brackets: CYP4F2 (7), GAA
(drugged, 22256), GCKR (68), RUNX1 (7437), TPH (4). As the
differing number of tool compounds indicates, some of these targets
are likely to be the focus of pre-existing drug development and
projects may still be ongoing or terminated. Once molecular proper-
ties of these compounds are considered to have a favorable profile,
particularly concerning the required direction of therapeutic effect,
they could be investigated in animal models of GBD. Some specific
candidate molecules are discussed further below.
Other relevant phenotypes
Supplementary Table 4 shows the values observed for cases and
controls in BWHHS, ARIC and WHI in relation to relevant covariates
for the interpretation of our meta-analysis. Significant differences were
observed between cases and controls for both age and BMI in all three
cohorts, with the exception of WHI in relation to age. This is in
accordance with the known relation between these variables and GBD.
However, no significant differences were observed between cases and
controls in relation to height, hormone replacement therapy and statin
use. Significant differences were observed for diabetes status in ARIC
and WHI but not in BWHHS.
Figure 1 Pathway analysis relating GBD with SNPs associated with plasma
lipid levels. (a) GBD QQ plot for SNPs representing 65 independent loci
reported in a published study to influence plasma lipid levels. (b) Monte
Carlo analysis of the median log10 P-value when sampling 65 SNPs at
random from our IBC array meta-analysis (excluding SNPs with MAF
o0.05), 10 000 random samplings. The observed median was 1.49. The
median observed for the lipid set (b) was 1.06 (mean=1.07, SD=0.19).
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DISCUSSION
GBD is a common disease, with 4700 000 cholecystectomies per-
formed in the United States alone per year at a cost of approximately
$6.5 billion.6 This study, the largest genetic epidemiological analysis of
GBD conducted to date, shows that a substantial number of genotypes,
which associate with plasma lipid levels, also associate with risk of
GBD in women of European ancestry. Taken together with some of
their known functions, these data provide evidence of causal con-
tributions of metabolic pathways involving both cholesterol, inter-
mediary metabolism of fats, carbohydrates, and phospholipids in
relation to GBD. Overall, this systems genetics analysis, by establishing
causality of associations, shows that appropriate approaches to
reduction of total cholesterol including reduction of carbohydrate
and triglyceride substrate availability to the hepatocyte, should result
in a decrease in risk of GBD.
Discussion about the relevance of phenotypic definitions of GBD
based on questionnaires is shown in Supplementary Information.
From our examination of up to ~ 53 000 SNPs included in the IBC
array analysis, the most prominent SNPs, which reached array-wide
significance, were at the ABCG5/ABCG8 locus (Table 1). Signals in this
locus, at such small P-values, are reassuring as it is a known positive
control for GBD. The high density of SNP coverage of this locus in
IBC compared with conventional GWAS arrays, combined with the
large number of cases, allowed us to show conclusively (based on the
absence of LD and retention in a combined model for variable
selection) the presence of several mutually independent signals
in known functional sites. Our leading SNP, rs4953023:G4A
(P= 7.41× 10− 47, effect size= 0.734) is in perfect LD with the
previously reported rs11887534:G4C (NM_022437.2(ABCG8):
c.55G4C (p.Asp19His). This amino-acid variant is believed to be a
functional SNP, which increases cholesterol secretion and hence the
risk of super-saturation of bile. The rs4299376:G4T variant, also in
ABCG8, tags an independent effect, possibly reflecting an earlier report
of NM_022437.2(ABCG8):c.161A4G (p.Tyr54Cys) (r2 ~ 0.2 between
rs4299376:G4T and rs4148211:A4G in Europeans) on GBD in
Taiwanese. Two further independent SNPs were identified in ABCG5,
rs10439467:C4T in intron 10 and rs6720173:G4C NM_022436.2
(ABCG5)c.1810C4G (p.Gln604Glu). The ABCG5/ABCG8 transpor-
ter is important in regulating biliary cholesterol. Our identification of
further new alleles at this locus influencing gallstone risk emphasises
that an approach, which might target cholesterol secretion directly,
could be useful in GBD prevention, though adverse effects on TC and
LDLc levels would need to be avoided or countered. However, it does
not prove that reduction of total cholesterol will be successful, as
sequestration anywhere away from the biliary tree might have no
consequence for GBD risk. Furthermore, the impact of ABCG5/
ABCG8 is much greater in GBD than it is on LDLc levels. ABCG8 does
emerge in lipid GWAS but with a small effect, apparently because the
hepatocyte compensates increased secretion by increasing cholesterol
synthesis.
A pathway analysis of the gene loci reported here highlighted
extensive connectivity between ABCG5, ABCG8, RUNX1, CCL20 and
nuclear hormone receptors (PPARG, PPARD, LXRA and RAR) with
important roles in lipid homeostasis. The influence of thiazolidine-
dione drugs on gallstones has not been extensively studied, although
two preclinical studies of pioglitazone conflict, a study by Al-Azzawi
et al.28 showed a drug induced increase in gallbladder volume leading
to increased gallstone formation in mice, whereas another study
showed that the drug reduced gallstone formation in rats, by the
action on retinol-binding protein-4.29 Our findings highlight the
potential therapeutic importance of the network of interactions
between members of the PPAR family, ABCG5/8, CCL20 and RUNX1.
We evaluated all the associated loci for evidence of small molecule
druggability (Supplementary Methods). The protein products of
several loci reported here are potentially druggable, but RUNX1
(Runt-related transcription factor 1) may be of immediate interest
in a novel target for GBD. RUNX1 has an osteogenic role in the
pathology of osteoarthritis, which was downregulated by a thienoin-
dazole molecule (TD-198946) recently described by Yano et al.30
RUNX1 may also have a role in atherosclerotic plaque formation.31
It is intriguing to speculate that RUNX1 may have a similar role in the
gallstone matrix in GBD.
Our pathway analysis relies on prior knowledge of gene function;
however, we also describe potentially important associations in several
highly novel genes of unknown function. A strong genetic signal is
reported in TTC39B (rs686030:C4A), at array-wide significance, the
first report implicating this locus in GBD. A variant in tetratricopep-
tide repeat domain 39B (TTC39B) at 9p22, rs581080:C4G, has been
associated with levels of HDL cholesterol and with genotype-
expression association in the Global Lipids Consortium.26 Lower
TTC39B transcript levels and higher HDL cholesterol are evident in
humans32 and knockdown of TTC39B in murine models also showed
a clear increase in HDL.26 The function of TTC39B is unknown;
however, the gene shows predominant gastrointestinal expression and
the gallbladder was the second most highly expressed tissue after the
skin, providing further support for a role of this novel gene in GBD.
Our results showing that the TTC39B association is attenuated after
HDL adjustment are consistent with HDL either mediating the
association with GBD or acting as a confounder. Further studies are
required to elucidate this.
Therapeutic implications of our findings are shown in
Supplementary Information.
Discussion about our combined analysis of 65 independent loci for
blood lipid levels and GBD is presented in Supplementary
Information.
An overall system, from the perspective of the gallbladder, can be
described as three loops (Figure 2): first and most proximal, the
enterohepatic cholesterol circulation; second, the loops of hepatocyte
cellular homeostasis of cholesterol (and intermediary metabolism);
and more distally, the total body status and turnover of lipids. Each
known genetic perturbation represents an experiment of nature
showing the likely directional outcome of an equivalent environmental
or pharmacological intervention, similar to the causal role reported for
IL6R in relation to coronary heart disease.33 It is evident from the
above that enhancing cholesterol breakdown, reducing synthesis and
reducing reuptake from plasma should reduce GBD risk, although the
third strategy would not be attractive from a vascular perspective. It is
notable that fibrate usage to reduce plasma triglycerides, increases
GBD risk apparently through increasing cholesterol synthesis and
hence flux through the biliary tree. The LIPC and GCKR data suggest
that reducing substrate availability for endogenous cholesterol synth-
esis should also be effective in modifying GBD risk.
Overall, these systems genetic analyses show that regulation of
hepatocyte cholesterol and intermediary metabolism exert causal
effects in GDB risk in women. For pragmatic reasons, we only
included women in our study and results may therefore only
generalise to women. Further studies in cohorts of men with similar
sample sizes would be required to extend our findings in men.
Preventive measures, dietary and pharmacological, should meet with
success considering the genetic evidence presented here that the
observed associations are causal.
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